Seminars in Perinatology
Volume 31, Issue 4 , Pages 223-226 , August 2007

The Impact of Autoimmune Disorders and Adverse Pregnancy Outcome

  • Federico Mecacci, MD

      Affiliations

    • Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Florence, Italy
    • Corresponding Author InformationAddress reprint requests to Federico Mecacci, MD, Careggi University Hospital, Department of Gynecology, Perinatology and Human Reproduction, Viale Morgagni 85, Florence I-50134, Italy.
    • ,
  • Annalisa Pieralli

      Affiliations

    • Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Florence, Italy
    • ,
  • Barbara Bianchi

      Affiliations

    • Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Florence, Italy
    • ,
  • Michael J. Paidas, MD

      Affiliations

    • The Yale Women and Children’s Center for Blood Disorders, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT.

References 

  1. Kamasta MA, Hughes GR. Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol. 1996;8:424–442
  2. Molad Y, Borkowski T, Monselise A, et al. Maternal fetal outcomes of lupus pregnancy: a prospective study of 29 pregnancies. Lupus. 2005;14:145–151
  3. Clowse ME, Magder ME, Witter F, et al. The impact of increased lupus activity on obstetrics outcomes. Arthritis Rheum. 2005;52:514–521
  4. Renaud C, de Montgolfier I, Vautier-Brouzes D, et al. Consequences perinatales des connectivites meternelles: etude prospective de 73 cas. Arch Pediatr. 2006;13:1386–1390
  5. Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by lupus erythematosus. Am J Obstet Gynecol. 2005;192:1897–1904
  6. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27:307–324
  7. Ostetnsen M. Disease specific problems related to drug therapy in pregnancy. Lupus. 2004;13:746–750
  8. Saar P, Hermann N, Muller-Ladner U, et al. Connective tissue diseases and pregnancy. Rheum. 2006;45:30–32
  9. Clowse MEB, Magder LS, Witter F, et al. Early risk factor for pregnancy loss in lupus. Obstet Gynecol. 2006;107:293–299
  10. Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet. 2001;357:1027–1032
  11. Le Thi Huong D, Welchesler B, Vauthier-Brouzes D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Am Rheum Dis. 2001;60:599–604
  12. Lockshin M, Reinitz E, Druzin ML, et al. Lupus pregnancy: a case-control prospective study demonstrating absence of lupus exacerbations during or after pregnancy. Am J Med. 1984;77:893-889
  13. Petri M, Howard D, Repke J, et al. The Hopkins Lupus Pregnancy Center: 1987-1991 update. Am J Reprod Immunol. 1992;28:188–191
  14. Khamashta MA, Ruiz-Irastorza G, Hughes GRV. Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am. 1997;23:15–30
  15. Empson M, Lassere M, Craig JC, et al. Recurrent pregnancy loss with antiphospolipid antibody: a systematic review of therapeutic trials. Obstet Gynecol. 2002;99:135–144
  16. Buyon J, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthr Rheumatol. 1992;35:55–61
  17. Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480–2487
  18. Brucato A, Frassi M, Franceschini F, et al. Risk of congenital block in newborns of mothers with anti-Ro/SSA antibodies delected by counterimmunoelectropheresis: a prospective study of 100 women. Arthrititis Rheum. 2001;44:1832–1833
  19. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658–1666
  20. Buyon JP, Clancy RM. Neonatal lupus syndromes. Curr Opin Rheumatol. 2003;15:535–541
  21. Waltuck J, Buyon JP. Autoantibody associated complete heart block: outcome in mothers and children. Ann Intern Med. 1994;120:544–551
  22. Finkelstein Y, Adler Y, Harel L, et al. Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. Ann Med Interne Paris. 1997;148:205–208
  23. Hughes G. The eradication of congenital heart block. Lupus. 2004;13:489
  24. Copel JA, Buyon JP, Kleinman CS. Successful in utero therapy of fetal heart block. Am J Obstet Gynecol. 1995;173:1384–1390
  25. Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atriventricular block without structural heart disease. Circulation. 2004;110:1542–1548
  26. Brucato A, Astori MG, Cimaz R, et al. Normal neuropsychological development of children with congenital complete heart block exposed or not in utero to high dose dexamethasone. Ann Rheum Dis. 2006;65:1422–1426
  27. Carvalho JS, Shinebourne EA, Kyle P. Efficacy unproved of maternal dexamethasone for fetal heart block. Am J Obstet Gynecol. 1996;175:502–503
  28. Pope RM, Yoshinoya S, Rutstein J, et al. Effects of pregnancy on the prognosis and serology of rheumathoid arthritis. Am J Med. 1983;74:973–979
  29. Buyon JP. The effects of pregnancy on autoimmune diseases. J Leuk Biol. 1998;63:281–287
  30. Chung L, Flyckt RL, Colon I, et al. Outcome of pregnancies compicated by systemic sclerosis and mixed connettive tissue disease. Lupus. 2006;15:595–599
  31. Steen VD. Pregnancy in women with systemic sclerosis. Obstet Gynecol. 1999;94:15–20
  32. Black CM, Stevens WM. Scleroderma. Rheum Dis Clin North Am. 1989;15:193–212

PII: S0146-0005(07)00064-X

doi: 10.1053/j.semperi.2007.05.005

Seminars in Perinatology
Volume 31, Issue 4 , Pages 223-226 , August 2007

Article Tools